Helene Fischer Rosenberg, M.D., Ph.D.
Inflammation Immunobiology Section
Building 50, Room 6241
50 South Drive
Bethesda, MD 20814
The Inflammation Immunobiology Section aims to explore the link between inflammation and infectious disease, specifically, the unique inflammatory sequelae elicited by respiratory virus pathogens. Our laboratory utilizes molecular, cellular, bioinformatics, and in vivo approaches to elucidate novel pathways and to gain insight into critical interactions.
As a major feature of these studies, our group developed the pneumonia virus of mice (PVM; family Paramyxoviridae) as a significant model of acute respiratory virus infection. In contrast to many human respiratory virus pathogens, PVM undergoes robust replication in the respiratory tracts of rodent species, and reproduces many clinical and pathologic features of severe human respiratory virus infection in inbred strains of mice. With this model, our group is pursuing studies aimed at elucidating novel inflammatory pathways and original immunomodulatory therapies, notably those featuring immunobiotic Lactobacillus species.
Related to these studies is our mainstay, the eosinophil, an enigmatic leukocyte whose role in innate immunity has recently undergone dramatic reconsideration. Eosinophils are best known for their contributions to the functional pathophysiology of allergic asthma; however, evolution tells us that the ability to induce pathology cannot be a raison d'être for any existing cell lineage. Several distinct lines of evidence have led us to consider the unrecognized beneficial impact provided by eosinophils in this setting, notably via their interactions with respiratory virus pathogens.
Dr. Rosenberg was awarded both M.D. and Ph.D. degrees from the Medical Scientist Training Program (MSTP) at The Rockefeller University / Cornell University Medical College (1984, 1985). Following postdoctoral research at Harvard University, she joined the National Institutes of Health in 1991, was granted tenure in 1998, and became a Section Chief in 2002.
Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9-22.
Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee JJ, Lee NA, Domachowske JB, Rosenberg HF. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood. 2014;123(5):743-52.
Ma M, Redes JL, Percopo CM, Druey KM, Rosenberg HF. Alternaria alternata challenge at the nasal mucosa results in eosinophilic inflammation and increased susceptibility to influenza virus infection. Clin Exp Allergy. 2018;48(6):691-702.
Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB, Rosenberg HF. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol. 2011;186(2):1151-61.
Percopo CM, Brenner TA, Ma M, Kraemer LS, Hakeem RM, Lee JJ, Rosenberg HF. SiglecF+Gr1hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice. J Leukoc Biol. 2017;101(1):321-328.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on December 6th, 2018